1Globe Biomedical (Hong Kong) Company Limited 8F, Block B, Techart Plaza, No.30 Xueyuan Road, Haidian District, Beijing, 100083, P.R. China Attention: Stella Wang Subject: Letter Agreement Regarding the Proposed Investment by CDH Dear Sir and/or Madam:Letter Agreement • December 22nd, 2020 • CDH Fund VI, L.P. • Pharmaceutical preparations • Delaware
Reference is hereby made to the share purchase agreement, dated as of the date hereof (the “SPA”), entered into by and among CDH Utopia Limited (the “Purchaser”) and 1Globe Biomedical (Hong Kong) Company Limited (the “Seller”), pursuant to which the Purchaser shall purchase from the Seller in aggregate 6,000,000 Common Shares (the “Sale Shares”) of Sinovac Biotech Ltd. (the “Company”). Capitalized terms used herein without definition shall have the same meanings as in the SPA.
SHARE PURCHASE AGREEMENTShare Purchase Agreement • December 22nd, 2020 • CDH Fund VI, L.P. • Pharmaceutical preparations • Delaware
This SHARE PURCHASE AGREEMENT (this “Agreement”) dated as of November 24, 2020 is made by and between CDH Utopia Limited, a company incorporated and existing under the laws of the Cayman Islands (the “Purchaser”), and 1Globe Biomedical (Hong Kong) Company Limited, a company incorporated under the laws of Hong Kong (the “Seller”). The Purchaser and the Seller are hereinafter referred to as the “Parties” and each a “Party.”
1Globe Biomedical (Hong Kong) Company Limited 8F, Block B, Techart Plaza, No.30 Xueyuan Road, Haidian District, Beijing, 100083, P.R. China Attention: Stella Wang Subject: Amendment to the Letter Agreement Regarding the Proposed Investment by CDH Dear...Letter Agreement Regarding the Proposed Investment by CDH • December 22nd, 2020 • CDH Fund VI, L.P. • Pharmaceutical preparations
Reference is made to (i) the share purchase agreement, dated as of November 24, 2020 (the “SPA”), entered into by and among CDH Utopia Limited (the “Purchaser”) and 1Globe Biomedical (Hong Kong) Company Limited (the “Seller”), pursuant to which the Purchaser shall purchase from the Seller in aggregate 6,000,000 Common Shares (the “Sale Shares”) of Sinovac Biotech Ltd. (the “Company”) and (ii) the letter agreement, dated as of November 24, 2020 (the “Side Letter”) issued by the Purchaser and CDH Investment Advisory Private Limited (the “CDH Guarantor”) to the Seller. Capitalized terms used herein without definition shall have the same meanings as in the SPA and the Side Letter.
JOINT FILING AGREEMENTJoint Filing Agreement • December 22nd, 2020 • CDH Fund VI, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. Each of the undersigned acknowledges that it shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
